chemical

Sitravatinib MGCD516

HY-16961

10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg

111; 80; 120; 300; 490; 820 USD

Sitravatinib MGCD516

Chemical

10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg

111; 80; 120; 300; 490; 820 USD

Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC 50 s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively [1] . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment [2] .

99.85%

Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month.